Yingjia Hu, Jian Li, Xinyi Wang, Hongfei Ji, Xingjian Niu
{"title":"利用炎症特征：炎症性乳腺癌的生物标志物综述。","authors":"Yingjia Hu, Jian Li, Xinyi Wang, Hongfei Ji, Xingjian Niu","doi":"10.1093/qjmed/hcaf219","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammatory breast cancer (IBC) is a highly aggressive breast cancer subtype characterized by rapid progression and poor survival outcomes. In recent years, research on the clinical and molecular features of IBC has brought new hope for its diagnosis and treatment. However, the prognosis of IBC remains extremely poor and novel biomarkers to identify the individual characteristics of patients with IBC are warranted. This review discussed the latest research on IBC biomarkers, especially the unique clinical IBC characterization-related biomarkers, including tumor emboli-related markers and tumor microenvironment (TME)-related markers. Biomarkers based on immune cells in the TME, such as tumor-associated macrophages (TAMs), tumor-infiltrating lymphocytes (TILs), mast cells, cytokines, and chemokines (e.g., CCL2), may be involved in the development, progression, and treatment resistance of IBC. This study also identified effective biomarkers for IBC and emphasized unique clinical IBC characterization-related biomarkers that may provide strong evidence in IBC diagnosis, prognosis, and therapeutics.</p>","PeriodicalId":20806,"journal":{"name":"QJM: An International Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Harnessing the Inflammatory Signature: A Review for Biomarkers in Inflammatory Breast Cancer.\",\"authors\":\"Yingjia Hu, Jian Li, Xinyi Wang, Hongfei Ji, Xingjian Niu\",\"doi\":\"10.1093/qjmed/hcaf219\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Inflammatory breast cancer (IBC) is a highly aggressive breast cancer subtype characterized by rapid progression and poor survival outcomes. In recent years, research on the clinical and molecular features of IBC has brought new hope for its diagnosis and treatment. However, the prognosis of IBC remains extremely poor and novel biomarkers to identify the individual characteristics of patients with IBC are warranted. This review discussed the latest research on IBC biomarkers, especially the unique clinical IBC characterization-related biomarkers, including tumor emboli-related markers and tumor microenvironment (TME)-related markers. Biomarkers based on immune cells in the TME, such as tumor-associated macrophages (TAMs), tumor-infiltrating lymphocytes (TILs), mast cells, cytokines, and chemokines (e.g., CCL2), may be involved in the development, progression, and treatment resistance of IBC. This study also identified effective biomarkers for IBC and emphasized unique clinical IBC characterization-related biomarkers that may provide strong evidence in IBC diagnosis, prognosis, and therapeutics.</p>\",\"PeriodicalId\":20806,\"journal\":{\"name\":\"QJM: An International Journal of Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.4000,\"publicationDate\":\"2025-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"QJM: An International Journal of Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/qjmed/hcaf219\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"QJM: An International Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/qjmed/hcaf219","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Harnessing the Inflammatory Signature: A Review for Biomarkers in Inflammatory Breast Cancer.
Inflammatory breast cancer (IBC) is a highly aggressive breast cancer subtype characterized by rapid progression and poor survival outcomes. In recent years, research on the clinical and molecular features of IBC has brought new hope for its diagnosis and treatment. However, the prognosis of IBC remains extremely poor and novel biomarkers to identify the individual characteristics of patients with IBC are warranted. This review discussed the latest research on IBC biomarkers, especially the unique clinical IBC characterization-related biomarkers, including tumor emboli-related markers and tumor microenvironment (TME)-related markers. Biomarkers based on immune cells in the TME, such as tumor-associated macrophages (TAMs), tumor-infiltrating lymphocytes (TILs), mast cells, cytokines, and chemokines (e.g., CCL2), may be involved in the development, progression, and treatment resistance of IBC. This study also identified effective biomarkers for IBC and emphasized unique clinical IBC characterization-related biomarkers that may provide strong evidence in IBC diagnosis, prognosis, and therapeutics.
期刊介绍：
QJM, a renowned and reputable general medical journal, has been a prominent source of knowledge in the field of internal medicine. With a steadfast commitment to advancing medical science and practice, it features a selection of rigorously reviewed articles.
Released on a monthly basis, QJM encompasses a wide range of article types. These include original papers that contribute innovative research, editorials that offer expert opinions, and reviews that provide comprehensive analyses of specific topics. The journal also presents commentary papers aimed at initiating discussions on controversial subjects and allocates a dedicated section for reader correspondence.
In summary, QJM's reputable standing stems from its enduring presence in the medical community, consistent publication schedule, and diverse range of content designed to inform and engage readers.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
